（原标题："沸腾"！又有两只，暴涨100%！） 【导读】又有两只基金业绩翻倍，年内"翻倍基"增至4只 中国基金报记者 张燕北 "翻倍基"又增加两只！ 创新药板块爆发，相关基金业绩上涨。截至7月17日，中银港股通医药A、永赢医药创新智选A年内单位 净值涨幅超100%，分别为年内第三只和第四只"翻倍基"。 受访基金经理表示，中期看好创新药板块的景气度。对于绝大部分中国创新药企业而言，能否进入新药 市场空间最大的欧美医药工业体系或是决定未来胜负的关键。 今年以来，重仓创新药的基金业绩领跑全市场。 除了上述四只"翻倍基"之外，截至7月17日，共计20只基金（仅统计主代码）年内单位净值涨幅超过 80%，绝大多数为聚焦创新药行业的主动或被动产品。 年内再添两只"翻倍基" 7月17日，创新药概念股强势爆发。当日，A股创新药板块指数涨幅超过3%，近20只相关概念股涨停或 涨幅超过10%；港股创新药多股创新高。 受此带动，一批医药主题基金当日净值大涨，助推年内业绩走高。截至7月17日收盘，中银港股通医药 A年内单位净值增长率达103.61%，永赢医药创新智选A涨幅达102.12%，成功跻身"翻倍基"阵营。 此前，汇添富香港优势 ...

7月17日，创新药概念股强势爆发。当日，A股创新药板块指数涨幅超过3%，近20只相关概念股涨停或涨幅超过10%；港股创新药多股创 新高。 【导读】又有两只基金业绩翻倍，年内"翻倍基"增至4只 中国基金报记者 张燕北 "翻倍基"又增加两只！ 创新药板块爆发，相关基金业绩上涨。截至7月17日， 中银港股通医药A、永赢医药创新智选A 年内单位净值涨幅超100%，分别为年内第 三只和第四只"翻倍基"。 受访基金经理表示，中期看好创新药板块的景气度。对于绝大部分中国创新药企业而言，能否进入新药市场空间最大的欧美医药工业体系 或是决定未来胜负的关键。 年内再添两只"翻倍基" 受此带动，一批医药主题基金当日净值大涨，助推年内业绩走高。截至7月17日收盘， 中银港股通医药A年内单位净值增长率达 103.61%，永赢医药创新智选A涨幅达102.12%，成功跻身"翻倍基"阵营。 除了上述四只"翻倍基"之外，截至7月17日，共计20只基金（仅统计主代码）年内单位净值涨幅超过80%，绝大多数为聚焦创新药行业的 主动或被动产品。 主动产品中，有四只基金年内单位净值涨幅超90%，年内业绩也有望翻倍，分别为华安医药生物（96.52%），中 ...

Core Views - The report indicates that the A-share market is experiencing a structural rally, with a focus on sectors with solid earnings support, particularly in innovative pharmaceuticals and technology sectors like robotics and CPO [2][11] - The upcoming important meeting is expected to emphasize macroeconomic policy adjustments, with potential increases in funding for infrastructure and support for strategic emerging industries such as AI and semiconductors [3][12] Market Overview - On Thursday, the three major indices in the A-share market collectively rose, with the Shenzhen Composite Index and the ChiNext Index showing stronger performance, while financial stocks weighed on the Shanghai Composite Index [5][11] - The market sentiment remains active, with a total trading volume of 15,394 billion, and the Shanghai Composite Index closing at 3,516.83 points, up 0.37% [6] Sector Analysis - The pharmaceutical sector saw significant gains, driven by supportive policies for innovative drugs and a favorable environment for commercialization, with expectations for continued growth in the second half of 2025 [7][11] - The optical communication module and CPO sectors are also highlighted as having strong growth potential, supported by advancements in AI computing and data center upgrades [8][11] - The aerospace and defense sector is expected to remain attractive, with government support for modernization and increased defense budgets, alongside geopolitical tensions that may act as catalysts for growth [9][10] Investment Opportunities - Investors are advised to focus on several key areas for potential investment: 1. Technology innovation sectors such as robotics, AI, and digital economy [4][13] 2. Industries benefiting from de-involution, including renewable energy and new energy vehicles [4][13] 3. Areas related to consumption upgrades and policy benefits, such as innovative pharmaceuticals and smart home devices [4][13] 4. Stocks with expected strong mid-year performance, although the intensity of speculation may decrease as earnings forecasts conclude [4][13]

【导读】狂买这些股， 又一批绩优基金经理二季报披露！ 中国基金报记者 曹雯璟 伴随基金二季报密集披露，绩优基金经理的最新持股变动、投资策略，以及对下半年的布局思路浮出水面。 根据二季报，该基金重点布局制造业、新能源、新技术等。具体来看，与一季度相比，五洲新春、汉威科技分别遭减仓93.11万股、21万 股，肇民科技、隆盛科技、北特科技、祥鑫科技、浙江荣泰、斯菱股份等新晋十大重仓股。 | 排名 | 证券代码 | 证券名称 | 持仓数量 | 持仓变动 | 持仓变动幅度 | 持仓市值 | 持仓占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 300953.SZ | 震裕科技 | 547.01万股 | 216.8万股 | 65.65% | 5.54亿元 | 5.10% | | 2 | 002779.SZ | 中坚科技 | 611.26万股 | 195.1万股 | 46.88% | 4.6 乙元 | 4.24% | | 3 | 300007.SZ | 汉威科技 | 1125.03万股 | -21万股 | -1.83% | 4.57亿元 | 4.20% ...

无论是短期刺激因素驱动行业上涨，还是中长期的行业发展，创新药未来三年都有望迎来大级别的投资 机会。 二季度，创新药行业持续走强。尽管受到关税、特朗普希望降低药价等多次扰动，但是创新药行业依然 持续上涨。创新药行业年初以来的涨幅大幅度超越同类型的风险资产AI板块、机器人板块的涨幅，引 发市场的高度关注。 7月18日，持续看好创新药的周思聪管理的产品——平安医疗健康混合型证券投资基金发布二季报，该 产品上半年取得57.41%的亮眼业绩。 值得一提的是，该产品在周思聪的管理下，净值于近日突破此前2021年的最高点，创下产品成立以来的 净值新高。截至7月17日，该产品A类份额最新净值为2.8764。 为何创新药能持续上涨？周思聪在二季报中表示，政策、业绩、出海、行业数据等多重因素催化创新药 持续上涨。 政策方面，医保局鼓励创新的政策导向持续，创新药持续迎来政策利好，创新药国内审批显著提速。业 绩方面，一季报多家大型创新药企业宣布盈利或者即将盈利，极大的提振了市场对于创新药板块的信 心。出海方面，中国创新药出海势头强劲，二季度多单市场高度关注的创新药对外授权落地，首付款及 总金额均大超市场预期，今年上半年国产创新药出海 ...

Core Viewpoint - Anker Innovations is exploring equity financing in the Hong Kong capital market, reflecting a growing trend of A-share companies listing in Hong Kong, with 10 companies having done so by July 17 this year [1] Group 1: A-share Companies Listing in Hong Kong - There has been a surge in A-share companies listing in Hong Kong, with 41 companies currently processing their listing applications as of mid-July [4] - The increase in A-share companies seeking to list in Hong Kong is attributed to policy support and the need for companies to expand their financing channels and international presence [4][6] - The Hong Kong IPO market has seen significant activity, with the total fundraising amount leading globally in the first half of the year [4] Group 2: Characteristics of Newly Listed A+H Companies - The newly listed A+H companies in Hong Kong this year are characterized by high market capitalization, with 9 out of 10 having a market value exceeding 10 billion yuan, and 5 exceeding 100 billion yuan [7] - These companies have demonstrated strong dividend capabilities and a focus on technology, enhancing their influence on the Hong Kong market [7] - A significant portion of the A+H companies are state-owned enterprises, with 68.13% of the 160 A+H companies being state-owned as of July 17 [7] Group 3: AH Share Premium Trends - The AH share premium has been on a downward trend, with 96.88% of A+H companies showing a premium of A-shares over H-shares as of July 17 [8] - The Hang Seng Shanghai-Shenzhen-Hong Kong Stock Connect AH share premium index was reported at 127.65, indicating that A-shares are, on average, 27% higher than H-shares [8] - The decline in AH share premium is attributed to differences in investor structure and trading mechanisms between A-shares and H-shares [8][9] Group 4: Future Outlook - It is anticipated that the trend of A-share companies listing in Hong Kong will continue over the next 2 to 3 years, supported by ongoing regulatory optimizations and market synergies [5][6] - The AH share premium is expected to continue narrowing, with factors such as increased southbound capital inflow and improved market conditions contributing to this trend [9]

Group 1 - The market shows a structural opportunity with indices rising due to strong performance in select sectors, while over 3000 stocks are experiencing adjustments [1][4] - The rare earth sector is notably strong, with companies like Jiu Wu Gao Ke hitting the daily limit up, supported by supply-demand dynamics and policy focus, alongside increasing demand from the new energy and military sectors [3][4] - The lithium mining sector is also gaining traction, with companies like Fu Miao Technology reaching the daily limit up, driven by a recovery in the new energy supply chain and stable lithium prices [3][4] Group 2 - The military industry is active, with Tian Qin Equipment rising over 12%, reflecting its connection to geopolitical and policy factors, although it may experience volatility [3][4] - Some sectors, such as innovative pharmaceuticals and photovoltaics, are facing declines, indicating a normal market rotation as funds shift focus [3][4] - The overall market dynamics suggest that while some sectors are performing well, others are consolidating, and investors should assess the fundamental support of their holdings [4]

A股三大指数震荡走高，截至午盘，沪指涨0.34%，深成指涨0.30%，创业板指涨0.26%，北证50指数跌0.48%，沪深京三市半日成交 额10293亿元，较上日放量1183亿元。全市场超3000只个股下跌。 板块题材上，稀土、锂矿、军工板块走高，创新药、光伏板块调整。 盘面上，稀土板块全线走高，久吾高科（300631）20CM涨停，东方锆业（002167）、华宏科技（002645）等涨停封板，北方稀土 （600111）触及涨停，股价创3年新高。锂矿板块持续走强，富淼科技20CM涨停，盛新锂能（002240）、金圆股份（000546）涨停 封板。军工板块走高，天秦装备（300922）涨超12%，建设工业（002265）封板。创新药板块震荡调整，广生堂（300436）、之江 生物跌超5%。光伏板块调整，亚玛顿（002623）跌超8%。 涨停天梯榜： 【8连板】 上纬新材。 【3连板】 海星股份（603115）。 【2连板】 延华智能（002178）、北化股份（002246）、建设工业、沧州大化、海航科技（600751）、汉商集团（600774）、人民 同泰（600829）、美邦股份（605033）。 最强风口榜 ...

2025年上半年，在A+H股及新经济企业密集赴港上市推动下，港交所锣声迭起。 智通财经APP了解到，今年上半年，港股市场共完成了42宗首次公开招股发行，合计募集资金1071亿元 （港元，下同），募资金额同比增长约700%，较2024年全年增幅约22%，募资规模暂列全球第一。值 得一提的是，2025年上半年，全球10大IPO中，有4宗IPO来自香港。 在这一盛况的背后，很大程度源于基石投资者的深度参与。作为港股IPO市场的关键参与主体，其在市 场中的布局与动向，不仅是衡量市场热度的重要指标，更在很大程度上反映了资本对企业价值的深度判 断，同时对新股发行的成功与否以及后续市场表现起着至关重要的作用，因此对其进行分析具有重要的 市场意义。 智通财经APP梳理发现，2025年上半年港股IPO基石投资呈现三大显著特点。 一是基石投资者"扎堆"现象突出。数据显示，42家港股IPO企业中，有36家引入共计189家基石投资者， 占比高达85.71%，这一数字远超往年水平。452.02亿港元的基石投资总额，占全市场超过42%的募资规 模，展现出资本对港股市场的强烈信心。其中，引入5家及以上基石投资者的公司达到16家。宁德时代 ...

热点板块：展望 7 月 A 股，可能仍是事件驱动的主题性行情，但板块间将出现高低切换。6 月末创 新药和银行等热门板块出现震荡回调，但 TMT、先进制造等板块开始超跌反弹，虽然 7 月预计仍是事 件驱动的主题性行情，但板块高低切换却是大概率事件。1）促进消费扩大内需是 2025 年的重点任务， 虽然大消费方向年报和一季报表现相对平淡，但市场对后续政策对冲仍有期待，这将是 2025 年大消费 方向的重要看点。关注乳制品、IP 消费、休闲旅游、医美等基本面景气度较高的板块。2）机器人国产 化和走进老百姓生活依然是 2025 年比较确定的趋势，机器人产品将从人形机器人向四足机器人、功能 型机器人扩展。以此带来的传感器、控制器、灵巧手等板块的阶段性机会将会反复出现。7 月特斯拉将 公布财报，且市场预期特斯拉人形机器人版本有可能更新，或将成为机器人板块新催化剂。3）半导体 国产化仍是大势所趋，关注其中的半导体设备、晶圆制造、半导体材料、IC 设计等。4）军工板块 2025 年存在订单回升的预期，大部分军工子板块如地面装备、航空装备、军工电子等一季报已经出现触底迹 象。5）创新药经历了近 4 年的调整后逐步迎来收获期，自 ...